BioEscalator Bulletin - Autumn 2025
10 September 2025
Stay informed with the latest BioEscalator updates, tenant and alumni news in the Autumn 2025 edition of the BioEscalator Bulletin.
Omos Biosciences joins the BioEscalator community to tackle cancer earlier
9 September 2025
We are delighted to welcome Omos Biosciences as the newest member of the BioEscalator community. The company has ambitious plans to transform cancer prevention by intervening at the pre-cancerous stage.
OMass Therapeutics enters into exclusive collaboration and license agreement with Genentech to develop and commercialise therapies for inflammatory bowel disease
1 September 2025
Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.
Moa develops groundbreaking category of crop protection; signs partnership deal with Gowan
25 August 2025
OXFORD UK: Moa Technology today announces its discovery of chemistries which could become an entirely new category of products to help farmers protect their harvests more safely, sustainably and effectively.
Green is the new gold: Infinitopes awarded gold LEAF accreditation
21 August 2025
Infinitopes has achieved the gold standard among the latest awardees for the Laboratory Efficiency Assessment Framework (LEAF), an innovative initiative to improve laboratory efficiency. As the second BioEscalator tenant to earn this accreditation, they follow in the footsteps of 2023/24 winner, Exogene.
Congratulations Alethiomics, the BioEscalator’s most recent graduate
19 August 2025
We’re proud to celebrate the graduation of Alethiomics, a University of Oxford spin-out dedicated to developing innovative treatments for blood cancers, as they move from the BioEscalator to their new home at Abingdon Science Park.
Innovate UK feature Infinitopes in recent case study
6 August 2025
Infinitopes received Innovate UK funding through the Investor Partnership Programme, which was pivotal to building and testing their cutting-edge discovery platform, and the Cancer Therapeutics Programme, to design, prepare and execute its phase I clinical trial, that scientists hope will be practice-changing.
OMass Therapeutics appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
5 August 2025
Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.
An insight into our sixth annual Pitch Battle - with competition as intense as ever!
30 July 2025
It was an afternoon of high drama as BioEscalator tenants took to the floor in our recent annual Pitch Battle to compete for the Best Pitch prize, sponsored by Oxford North, and a range of other accolades.
U-Ploid Biotechnologies featured in EQT Foundation's 25 Scientific Founders Pushing the Frontiers of Impact 2025 report
27 July 2025
U-Ploid Biotechnologies is rewriting the script on fertility treatments, tackling the root cause of age-related egg decline with groundbreaking science.
Business Apprentice Becson joins the BioEscalator
23 July 2025
Who knew? Young adults do listen to their parents, and the BioEscalator is very glad about that. Becson Ody, our first Business Administration & Reception apprentice, found out about apprenticeships through his father, who is a ‘big advocate’.
Biotech start-up Ochre Bio relocates to Alexandria Center® for Life Science – New York City
20 July 2025
JLL announced today that it has completed a sublease for growing U.K.-based biotech company Ochre Bio at 430 East 29th St. within the Alexandria Center® for Life Science – New York City.
OMass Therapeutics presents positive preclinical data for its Best-in-class MC2 program at ENDO 2025
13 July 2025
Oxford, United Kingdom – 14th July 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces positive preclinical data for OMS1620, its lead program targeting the melanocortin-2 (MC2) receptor, at ENDO 2025, the Annual Endocrine Society Meeting, taking place in San Francisco from 12-15 July.
BioEscalator Portfolio 2025
1 July 2025
The BioEscalator is very proud to be home to a stellar collection of companies using cutting-edge science to tackle profound medical challenges. Our new Portfolio 2025 brings them together to showcase their innovative approaches and provide a valuable guide for potential investors and partners.
Dr Quin Wills appointed as Ochre Bio CEO
29 June 2025
Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO.
BioEscalator Bulletin - Summer 2025
4 June 2025
Stay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Summer 2025 edition of the BioEscalator Bulletin.
Ochre Bio appoints ex-Eli Lilly and AstraZeneca VP as Non-Executive Director
28 May 2025
The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics.
PepGen to focus on development of promising DM1 program following 10 mg/kg PGN-EDO51 update
27 May 2025
PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs. PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild. DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.
Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer
26 May 2025
Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business Officer with immediate effect.
Welcome, Sandbox Bioscience, to the BioEscalator Community!
22 May 2025
We are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.